The same advances in breast cancer treatment that have dramatically improved survival in recent years have also left a growing number of women vulnerable to potentially fatal cardiovascular problems.

News

The same advances in breast cancer treatment that have dramatically improved survival in recent years have also left a growing number of women vulnerable to potentially fatal cardiovascular problems.
A recent study found over 18% of patients with relapsed or refractory multiple myeloma treated with a proteasome inhibitor were faced with cardiovascular adverse events.
A recent study compared the relative risk of cardiovascular ischemic events in patients with prostate cancer after surgical castration vs gonadotropin-releasing hormone agonist therapy.
A recent analysis examined the potential correlation between preexisting cardiovascular conditions and risk of heart failure in survivors of non-Hodgkin lymphoma.

Research in Review

Initiatives to reduce cardiotoxicity among childhood patients with cancer treated more recently have had a measurable impact over time.
Two kinds of heart medications, angiotensin-converting enzyme (ACE) inhibitors and beta blockers, can help to prevent a decline in heart function from breast cancer treatment, according to new research published in the Journal of Clinical Oncology.
Researchers have identified a serious and potentially fatal adverse event associated with immunology drugs.
European Society of Cardiology has published a novel position paper tackling the problem of cardiac toxicity associated with anticancer therapies.
Subscribe to Cardio-Oncology